Skip to main content

Table 3 Soluble markers

From: No evidence of a synergistic effect of HIV infection and diabetes mellitus type 2 on fat distribution, plasma adiponectin or inflammatory markers

 

HIV + DM2+

HIV + DM2-

Controls with DM2

Healthy controls

P

Adiponectin (μg/mL)

9.79 (8.02–11.56)

13.83 (10.07–17.06)*

8.63 (6.96–10.29)

14.96 (12.80–17.11)*

< 0.001

IL-6 (pg/mL)

2.16 (1.16–3.15)

1.04 (0.67–1.41)*

3.89 (0.89–8.66)

0.91 (0.72–1.11)*

0.050

TNF-alfa (pg/mL)

3.24 (2.66–3.82)

2.92 (2.01–3.84)

4.02 (1.32–6.73)

2.29 (2.07–2.51)

0.112

sCD14 (ng/mL)

2333 (1935–2732)

2218 (1912–2525)

1461 (1277–1644)*

1504 (1302–1706)*

< 0.001

  1. Soluble markers presented as mean (95%CI) before log transformation. P-value represent one-way ANOVA analyses after log transformation followed by t-test for comparison between HIV + DM2+ and the 3 control groups when ANOVA test was *p < 0.05 compared to HIV+DM2+
  2. Abbreviations: HIV + DM2+ People living with HIV with diabetes mellitus type 2, HIV + DM2- People living with HIV without diabetes mellitus type 2, IL-6 Interleukin-6, TNF- α Tumor necrosis factor-alfa, sCD14 Soluble CD14, DM2 Diabetes mellitus type 2